soul trial oral semaglutide cardiovascular outcomes 2024 results nejm reduces heart failure risk in type 2 diabetes patients soul trial oral semaglutide cardiovascular

Important safety considerations include: Not for use during pregnancy or breastfeeding Not for people under 18 years Not to be used alongside other GLP-1 receptor agonists Caution in people with a history of pancreatitis or gallbladder disease Risk of dehydration due to gastrointestinal side effects Potential hypoglycaemia risk when used with insulin or sulfonylureas Need for diabetic retinopathy monitoring in people with type 2 diabetes Suspected side effects should be reported via the MHRA Yellow Card Scheme

Shelf life: 36 months EFFECTS & MECHANISM -Ultilization of energy - Fatty acids are transported more into the cells for burning

Specifications and Usage Recommendations

Ozempic is licensed only for the treatment of type 2 diabetes

Suited for long-term weight management with broad patents

salivarius [40, 41]